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Antibiotic use and microbial resistance in health care-associated infections are increasing globally and causing health care
problems. Intensive Care Units (ICUs) represent the heaviest antibiotic burden within hospitals, and sepsis is the second
noncardiac cause of mortality in ICUs. Optimizing appropriate antibiotic treatment in the management of the critically ill in ICUs
became a major challenge for intensivists. We performed a surveillance study on the antibiotic consumption in 108 Polish ICUs.
We determined which classes of antibiotics were most commonly consumed and whether they affected the length of ICU stay and
the size and category of the hospital. A total of 292.389 defined daily doses (DDD) and 192.167 patient-days (pd) were identified.
Antibiotic consumption ranged from 620 to 3960 DDD/1000 pd. +e main antibiotic classes accounted for 59.6% of the total
antibiotic consumption and included carbapenems (17.8%), quinolones (14%), cephalosporins (13.7%), penicillins (11.9%), and
macrolides (2.2%), respectively, whereas the other antibiotic classes accounted for the remainder (40.4%) and included antifungals
(34%), imidazoles (20%), aminoglycosides (18%), glycopeptides (15%), and polymyxins (6%). +e most consumed antibiotic
classes in Polish ICUs were carbapenems, quinolones, and cephalosporins, respectively. +ere was no correlation between
antibiotic consumption in DDD/1000 patient-days, mean length of ICU stay, size of the hospital, size of the ICU, or the total
amount of patient-days. It is crucial that surveillance systems are in place to guide empiric antibiotic treatment and to estimate the
burden of resistance. Appropriate use of antibiotics in the ICU should be an important public health care issue.
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1. Introduction
Antibiotic use and microbial resistance in health care-
associated infections are increasing globally and, in Euro-
pean countries such as Poland, causing health care problems
[1–3]. Increasing antibiotic resistance results in increased
morbidity, mortality, and cost of health care [4, 5]. +is is
a common and alarming problem worldwide and in Poland.
ICU represents the heaviest antibiotic burden within the
hospital [6]. ICU is also recognized as a department which
creates, disseminates, and amplifies antibiotic resistance,
which is important from a microbiological point of view
[6, 7].
Data on antimicrobial consumption in Polish ICUs are
limited. Poland participated in the European Surveillance of
Antimicrobial Consumption (ESAC) project, collecting data
on antimicrobial consumption in ambulatory care and
hospital setting. Unfortunately, the last surveillance report
from 2014 contains only data on antimicrobial consumption
in ambulatory care. Poland also participated in the European
Point Prevalence Survey of Healthcare Associated Infections
and Antimicrobial Use (EU-PPS HAI&AU) in 2011 and in
2012 [7]. Deptułą et al. [8] showed a high prevalence of
health care-associated infections among patients hospital-
ized in both adult and pediatric Polish ICUs.+ey concluded
that there is a need for a national infection prevention
program in Poland for these groups. Based on the above
findings, we performed a surveillance study on the antibiotic
consumption in Polish ICUs. We aimed to assess the an-
tibiotic prescribing practices and the annual consumption of
antibiotics in adult ICUs.
2. Materials and Methods
Poland currently has 420 adult and 16 pediatric ICUs. All of
the ICUs were invited to participate in the surveillance
study, which was conducted between April 15, 2014, and
June 15, 2015. Survey questionnaires were sent to all ICUs.
Requested data included the number of patient-days in the
ICU, the mean length of ICU stay, and the antibiotic
consumption in 2014. Classification of hospitals and ICUs
was obtained from the National Health Fund and included
the type of hospital (district hospital, specialist hospital,
university hospital, or university hospital with a hematology
department), the number of hospital beds, and the number
of ICU beds. Data on antibiotic consumption were calcu-
lated dividing the amount of active substance by the amount
of DDD according to the WHO Collaborating Centre for
Drug Statistic Methodology. +e data received from the
participating ICUs in 2014 were then converted and
expressed in DDD/1000 patient-days.
+e regional Ethical Board reviewed and approved the
study protocol. +e need for informed consent was waived
due to the observational nature of the study.
+e majority of Polish ICUs are interdisciplinary.
According to the ECDC and EU-PPS HAI&AU protocol [7],
the participating ICUs were divided into groups depending
on the size of the hospital to which they belonged (<250
beds, 250–500 beds, and >500 beds). University hospitals
with and without a hematology department were considered
as separate groups.
2.1. Statistical Analysis. Nonparametric rank ANOVA test,
Kruskal–Wallis test, post hoc tests (for multiple compari-
sons), chi-square test, and multipartite tables were used as
appropriate for the biggest reliability of assessed relation
between selected factors and antibiotic consumption in
ICUs.
3. Results
In total, 134 adult ICUs sent their data for analysis. However,
queries were sent for any unclear information. If a query
remained unanswered, that particular ICU was removed
from the study. Finally, data from 108 ICUs (25.7% of all
adult ICUs) were included in the study. +e information
from each ICU was reviewed, and the data were then
converted to DDD/1000 patient-days. A total of 292,389
DDD and 192,167 patient-days were included in the
analysis.
Antibiotic consumption varied from 620 to 3960
DDD/1000 patient-days, with a median of 1338 DDD/1000
patient-days and a mean of 1520 DDD/1000 patient-days
(Figure 1).+e differences in the value of DDD/1000 patient-
days between various hospitals were not statistically sig-
nificant (p � 0.1287), most likely due to the high variability
of results observed within the ICUs.
In hospitals with less than 250 beds, 250–500 beds, and
more than 500 beds, the mean amount of DDD/1000
patient-days was 1310, 1520, and 1490, respectively. How-
ever, the highest consumption (without statistical signifi-
cance) was observed in university hospitals and university
hospitals with a hematology department.
In university hospitals, the mean amount of DDD/1000
patient-days was 1940, whereas in university hospitals with
a hematology department, the mean amount of DDD/100
patient-days was 2% lower (Figure 1).
+e main antibiotic classes accounted for 59.6% of the
total antibiotic consumption. Carbapenems ranged from 1%
to 54% of the total antibiotics consumed with a mean of
17.8%, quinolones ranged from 1% to 44% with a mean of
14%, cephalosporins ranged from 1% to 45% with a mean of
13.7%, penicillins ranged from 1% to 58% with a mean of
11.9%, and macrolides ranged from 1% to 15% with a mean
of 2.2%, whereas the other antibiotic classes accounted for
the remainder (40.4% of total antibiotic consumption). +e
mean values for this distribution are illustrated in Figure 2.
+e other antibiotic classes accounted for 40.4% of the
total antibiotic consumption and included antifungals
(34%), imidazoles (20%), aminoglycosides (18%), glyco-
peptides (15%), and polymyxins (6%). Details of this
comparison are shown in Figure 3.
Figure 4 displays the distribution of the various classes of
antibiotics used in each ICU. Each ICU has been assigned an
2 Canadian Journal of Infectious Diseases and Medical Microbiology
individual number. e main antibiotic classes are shown in
dierent colours. e size and colour of each column cor-
respond to the amount and type of antibiotic class used. e
ICUs are presented in order of decreasing antibiotic use.
e dierences in the distribution of antibiotic classes
between ICUs were not statistically signicant, except for
macrolides and third-generation cephalosporins, which
diered signicantly between hospitals with more than 500
beds and university hospitals (p  0.037 and p  0.046,
resp.).
e most commonly used antibiotics expressed as
a percentage of total antibiotic consumption were mer-
openem and imipenem/cilastatin (19.6%) (meropenem 9.9%
and imipenem/cilastatin 9.7%), uconazole (13.3%), cipro-
oxacin (12.2%), metronidazole (7.7%), ceftriaxone (5.8%),
and vancomycin (5.4%).
e mean length of ICU stay in Poland ranged from 4.8
days to 35 days with a mean of 11.4 days. ere was no
correlation between mean length of ICU stay, size of the
hospital, size of ICU, antibiotic consumption in DDD/1000
patient-days, and the total amount of patient-days.
4. Discussion
To the best of our knowledge, this is the rst surveillance
study investigating the antibiotic prescribing practices and
the annual consumption of antibiotics in adult ICUs in
Poland. 108 ICUs took part in the study, which is 25.7% of all
ICUs in Poland. Our study shows that the three classes of
antibiotics most consumed in Polish ICUs are the carba-
penems, quinolones, and cephalosporins.
In addition, we found a high annual antibiotic pre-
scribing rate and a substantial variation in antibiotic con-
sumption between the ICUs. e antibiotic consumption
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Figure 1: Mean antibiotic consumption in Polish ICUs (data expressed in DDD/1000 patient-days).
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
17.8%
14% 13.7% 11.9%
2.2%
40.4%
Percentage of antibiotic consumption for the main antibiotic classes
Carbapenems Quinolones Cephalosporins Penicillins Macrolides Others
Figure 2: Distribution of total antibiotic consumption in Polish ICUs by main antibiotic classes.
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Figure 3: Distribution of antibiotic consumption in class “others”
expressed in percentage of antibiotic consumption. Five of the most
often used antibiotics in this group.
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was not dependent on the hospital size, type, or length of
ICU stay.
Similar studies on the annual consumption of antibiotics
in ICUs were also conducted in other European countries: in
Germany, the SARI Surveillance System [9] and in Sweden,
the ICU-STRAMA [10]. In comparison with these studies, in
Poland, the mean annual antibiotic consumption reached
1520 DDD per 1000 patient-days, which is higher compared
to Germany (1305 DDD/1000 pd in the SARI Surveillance
System) [9] or Sweden (1147 DDD/1000 pd in the ICU-
STRAMA report) [10]. In our study, antibiotic consumption
in the ICUs ranged from 620 to 3960 DDD/1000 patient-
days. is heterogeneity was also observed in a study in-
cluding 29 Swedish ICUs, where antibiotic consumption
ranged from 605 to 2134 DDD/1000 pd [10], and in
a German SARI Surveillance System where antibiotic con-
sumption varied from 463 to 2216 DDD/1000 pd [9].
However, the maximum annual antibiotic consumption in
Sweden was similar to that found in the German study (2134
DDD/1000 pd versus 2216 DDD/1000 pd) [10], while in our
study the consumption was higher, reaching 3960
DDD/1000 pd.
Our study revealed the extensive use of meropenem and
imipenem/cilastatin which are used most frequently (17.8%),
followed by uconazole (13.3%), ciprooxacin (12.2%), met-
ronidazole (7.7%), ceftriaxone (5.8%), and vancomycin (5.4%).
According to the ECDC Surveillance Report on anti-
microbial consumption during the period 2008–2012 in
Europe, the most frequently consumed class of antibiotics
was penicillins, followed by cephalosporin and quinolones
[2]. In our study, cephalosporins were consumed 25% less
often (13.7% versus 19%) and macrolides four times less
often, when compared to the data from the SARI study [9].
e consumption of carbapenems in Poland was 25% higher
in comparison with other countries in northern Europe [9].
e Polish Severe Sepsis Registry [11] showed that the most
frequent cause of septic shock in patients admitted to the
ICU was an intra-abdominal infection; hence, there is
a necessity of treating Gram-negative bacterial ora [12].
In our study, the most common antifungal drug used in
Polish ICUs was uconazole, accounting for 97% of all the
antifungal drugs. e reason for such high consumptions of
uconazole is multifarious. erapeutic management in the
prevention and treatment of fungal infections in Poland, as
in other countries, is obliged to rely on European [13] or
American guidelines [14]. However, in Polish ICUs, usage of
antifungal drugs is based on the presence of risk factors for
systemic fungal infections-Candida score [15], the re-
spiratory culture result, or because of long-lasting antibiotic
therapy. Due to the fact that it is used as prophylaxis for
a fungal infection, it is easier to implement a cheaper therapy
with the use of uconazole. However, uconazole can be
successfully used in hospitals because the majority of in-
fections are Candida albicans or Candida parapsilosis [7].
Echinocandins are left for targeted therapy or for patients in
whom there are indications; for example, they have a mul-
tisite colonization of Candida nonalbicans [16]. e study
showed for the rst time how often uconazole is used and
indicates the need to increase the awareness in the eld of
therapy for fungal infections. is is a very high gure when
compared to the 2012 ECDC surveillance on antimicrobial
consumption in Europe. is surveillance has also identied
11 European countries (61%), where uconazole alone
accounted for more than 50% of the total antifungal drugs
consumed. Poland seems to be a country with one of the
highest consumptions of uconazole [2]. Paying attention to
such high consumptions of uconazole is one of the greatest
achievements of this study.
Excessive use of carbapenems leads to higher antimi-
crobial resistance which results in the use of broad-spectrum
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Figure 4: Antibiotic classes used in each of the 108 ICUs participating in the study. ICUs are presented on the X-axis in the order of
decreasing antibiotic use.
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antibiotics in the ICU. +is is an unsettling phenomenon
which occurs in other countries in eastern and southern
Europe. +ese observations are consistent with the data
published in the annual report of the European Antimi-
crobial Resistance Surveillance Network (EARS-Net) [17].
+e results presented in this report are based on antimi-
crobial resistance data from invasive isolates reported to
EARS-Net by 30 European Union (EU) and European
Economic Area (EEA) countries in 2017 (data referring to
2016). As in previous years, the antimicrobial resistance
situation in Europe displays wide variations depending on
the bacterial species, antimicrobial group, and geographical
region. For several bacterial species-antimicrobial group
combinations, a north-to-south gradient and a west-to-east
gradient are evident in Europe. In general, lower resistance
percentages were reported by countries in the north, while
higher percentages were reported in the south and east of
Europe. +ese differences are most likely related to varia-
tions in antimicrobial use, infection prevention, and control
practices, and dissimilarities in diagnostic and health care
utilization patterns in the countries [17].
+e dynamics of antibiotic resistance are multifarious.
Antibiotic usage in the animal and plant industry is a major
contributor to antimicrobial resistance (AMR) [18]. Within
the hospital, the ICU represents the heaviest antibiotic burden
[6]. In the ICU setting itself, causes of AMRmay conveniently
be categorized by procedure-related, management-related,
and antibiotic-related factors. Procedure-related factors in-
clude central venous catheters [18, 19], and endotracheal
intubation for mechanical ventilation [16]. Management-
related factors include poor adherence to infection control
policy, lack ofmicrobiological surveillance with delayed/failed
recognition of resistant isolates [18, 20], patient overcrowding
[21], understaffing, and implicit spread of AMR through
human vectors [22], prolonged ICU length of stay [18, 23],
and pre-infection with resistant organisms at the time of ICU
admission [18, 23]. Antibiotic-related factors are related to the
appropriateness and duration of treatment. +e use of broad-
spectrum antibiotics, often as a first step in the treatment of
patients with suspected infections, has a documented re-
lationship with the development of antibiotic resistance
[18, 23, 24]. Similarly, the ease of access to certain antibiotic
classes, either through their availability over-the-counter in
certain countries (e.g., penicillins and fluoroquinolones) or
through unfounded clinician concerns of suspected bacterial
infection, leads to documented AMR, although causation
proves difficult at an individual patient level [18].
Variability in antibiotic prescribing cannot be explained
only by differences in the epidemiology of the community
and hospital infections or antimicrobial resistance patterns.
Socioeconomic and sociocultural factors, as well as the way
in which health care is funded or reimbursed, are likely to
influence antibiotic use [25, 26].
Mean length of ICU stay in our study ranged from 4.8 to
35 days with a mean of 11.4 days. +is is much longer than
the mean length of ICU stay in the SARI study in Germany
(4.8 days) [9]. +is may be due to the different severity of
patients admitted to the Polish ICUs. In the Polish Severe
Sepsis Registry, 4999 patients were registered during the 7-
year period (2003–2009) [27]. +ese patients were admitted
to the ICU in critical condition, and the majority of them
(89%) had a dysfunction of three or more organs. +e
APACHE II score on admission was 26 points. In the United
States, only 36% of identified patients were mechanically
ventilated at some point during their ICU stay [28]. In
Poland, the majority of patients (89%) admitted to the ICU
were intubated [27].
One of the reasons for the severe condition of patients
admitted to Polish ICUs is the lower accessibility to intensive
care beds, which is three times smaller in comparison to
other European countries [28]. In Western European
countries, the highest number of intensive care beds for
adults is in Germany—24 beds per 100 000 inhabitants [29].
In the United States, this number was 28 in 2007 [30, 31]. In
Poland, the number of intensive care beds per 100 000
inhabitants is 7.1 [28]. Less available beds are associated with
a delayed admission to the ICU, and as a consequence, more
organ dysfunction.
+is study has some important limitations. Participation
in the surveillance study was voluntary, and therefore se-
lection bias cannot be excluded. It is possible, that some
ICUs encountering higher antibiotic consumption and
higher resistance rates may be aware of the problem and did
not wish to take part in the surveillance.
Our study describes the amount of antibiotic con-
sumption in Polish ICUs. +e wide variation in consump-
tion between individual hospitals suggests that there is
a potential for quality improvement and benchmarking. We
also observed differences between our data and similar data
from other countries. Results from such assessments should
be distributed to both politicians and professionals in the
country. It is essential to perform regular assessments of
antibiotic consumption and antibiotic resistance in Polish
ICUs. Updating international guidelines for appropriate
antibiotic use and implementing these guidelines
(e.g., including internationally agreed-upon stewardship
programs) is one possibility.
Surveillance on continuous antibiotic consumption and
evaluation of prescribing patterns with feedback is partic-
ularly important. Surveillance on antibiotic consumption is
one of the main instruments for improving rational anti-
biotic use in ICUs at the regional and national level.
5. Conclusion
+e three classes of antibiotics most consumed in Polish
ICUs are the carbapenems, quinolones, and cephalosporins.
+e consumption of these 3 classes of antibiotics should be
limited and controlled in ICUs, considering the high risk of
antimicrobial resistance that involves their use.
Further research is required to determine the appro-
priate use of antibiotics in the ICU and should be an im-
portant safety and health care issue worldwide.
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Bołdys, Krzysztof Borzędzki, Roman Brachaczek, Marek
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Śliwa-Rak, Bernadet Tułaza, IzabelaWencel, DariuszWęgrzyn,
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